We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

8 hedge funds and large institutions have $111K invested in NeuroSense Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

60% more funds holding

Funds holding: 5 → 8 (+3)

4.69% less ownership

Funds ownership: 5.72% → 1.04% (-4.7%)

80% less capital invested

Capital invested by funds: $554K → $111K (-$444K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
+3
Holders Change %
+60%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$9.3K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.95K
3
Morgan Stanley
Morgan Stanley
New York
+$997
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$40

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$470K
2
Citadel Advisors
Citadel Advisors
Florida
-$8.78K
3
UBS Group
UBS Group
Switzerland
-$2.77K

NRSN Hedge Fund Activity: Q4 2023 in Review

8 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q4 2023, worth a combined $111K — down 80% from $554K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NRSN positions and 2 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $9.3K. The largest seller was Armistice Capital, exiting entirely with an estimated $470K sold.

  • 8 institutional investors held NeuroSense Therapeutics (NRSN) as of Q4 2023, up from 5 in Q3 2023.
  • Funds reported $111K of NeuroSense Therapeutics stock for Q4 2023, down 80% quarter-over-quarter.
  • 5 funds opened new NeuroSense Therapeutics positions in Q4 2023 and 2 closed out, a net change of +3 holders.
  • The largest NeuroSense Therapeutics buyer in Q4 2023 was HRT Financial, an estimated $9.3K added.
  • The largest NeuroSense Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $470K sold.

Based on aggregated 13F filings for Q4 2023.